JATT Acquisition (JATT) Competitors $2.90 -0.25 (-7.94%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends JATT vs. XBIT, SLDB, OPT, NBTX, ADCT, ENTA, ZURA, CMPX, MDWD, and INZYShould you be buying JATT Acquisition stock or one of its competitors? The main competitors of JATT Acquisition include XBiotech (XBIT), Solid Biosciences (SLDB), Opthea (OPT), Nanobiotix (NBTX), ADC Therapeutics (ADCT), Enanta Pharmaceuticals (ENTA), Zura Bio (ZURA), Compass Therapeutics (CMPX), MediWound (MDWD), and Inozyme Pharma (INZY). These companies are all part of the "pharmaceutical products" industry. JATT Acquisition vs. XBiotech Solid Biosciences Opthea Nanobiotix ADC Therapeutics Enanta Pharmaceuticals Zura Bio Compass Therapeutics MediWound Inozyme Pharma JATT Acquisition (NYSE:JATT) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability. Does the media refer more to JATT or XBIT? In the previous week, XBiotech had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 1 mentions for XBiotech and 0 mentions for JATT Acquisition. XBiotech's average media sentiment score of 1.11 beat JATT Acquisition's score of 0.00 indicating that XBiotech is being referred to more favorably in the news media. Company Overall Sentiment JATT Acquisition Neutral XBiotech Positive Is JATT or XBIT more profitable? XBiotech's return on equity of -15.99% beat JATT Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets JATT AcquisitionN/A -49.58% 2.84% XBiotech N/A -15.99%-14.85% Do insiders and institutionals believe in JATT or XBIT? 48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by company insiders. Comparatively, 33.1% of XBiotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better earnings and valuation, JATT or XBIT? JATT Acquisition has higher earnings, but lower revenue than XBiotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJATT AcquisitionN/AN/A$6.85MN/AN/AXBiotech$4.01M49.33-$24.56M-$1.08-6.01 Does the MarketBeat Community favor JATT or XBIT? XBiotech received 317 more outperform votes than JATT Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformJATT AcquisitionN/AN/AXBiotechOutperform Votes31769.98% Underperform Votes13630.02% SummaryXBiotech beats JATT Acquisition on 7 of the 9 factors compared between the two stocks. Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Get JATT Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JATT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JATT vs. The Competition Export to ExcelMetricJATT AcquisitionBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$50.03M$2.93B$5.07B$19.96BDividend YieldN/A1.91%4.99%3.49%P/E RatioN/A16.1687.8636.42Price / SalesN/A282.771,228.8217.94Price / Cash27.08169.3839.5121.28Price / Book-5.474.436.944.59Net Income$6.85M-$41.63M$119.12M$985.93M7 Day Performance-33.79%-4.73%-1.84%0.45%1 Month Performance-41.06%-6.53%-3.65%1.05%1 Year Performance-35.12%25.63%31.64%24.67% JATT Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JATTJATT AcquisitionN/A$2.90-7.9%N/A-29.5%$50.03MN/A0.003High Trading VolumeXBITXBiotech0.8946 of 5 stars$6.49-2.7%N/A+77.8%$197.82M$4.01M-6.01100Positive NewsSLDBSolid Biosciences3.3235 of 5 stars$4.95-0.2%$15.14+205.9%+108.4%$197.80M$8.09M-1.63100Analyst RevisionOPTOpthea2.074 of 5 stars$3.31+1.5%$12.00+262.5%+72.4%$193.30M$120,000.000.008NBTXNanobiotix2.3432 of 5 stars$4.07+7.7%$11.50+182.7%-33.5%$191.75M$39.18M0.00100Positive NewsADCTADC Therapeutics2.8805 of 5 stars$1.98-3.9%$8.25+316.7%+177.9%$191.45M$69.56M0.00310Positive NewsENTAEnanta Pharmaceuticals2.9547 of 5 stars$9.00-0.9%$20.00+122.2%+1.6%$190.71M$79.20M-1.67145ZURAZura Bio3.9055 of 5 stars$2.90-7.9%$15.80+444.8%-35.1%$189.34MN/A0.003Analyst ForecastCMPXCompass Therapeutics3.4294 of 5 stars$1.37-3.5%$6.75+392.7%-18.9%$188.50MN/A0.0020MDWDMediWound1.8385 of 5 stars$16.78+6.2%$29.00+72.8%+96.0%$181.06M$18.69M-7.7780Upcoming EarningsINZYInozyme Pharma1.2302 of 5 stars$2.79-0.7%$15.71+463.2%-28.5%$179.23MN/A0.0050 Related Companies and Tools Related Companies XBIT Alternatives SLDB Alternatives OPT Alternatives NBTX Alternatives ADCT Alternatives ENTA Alternatives ZURA Alternatives CMPX Alternatives MDWD Alternatives INZY Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:JATT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JATT Acquisition Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share JATT Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
